Colorado Blood Cancer Institute

08/28/2025

We’re proud to share that the Colorado Blood Cancer Institute was recently highlighted in the Washington Business Observer for our role in advancing life-saving research.

Our team is honored to participate in groundbreaking clinical trials, including studies that explore innovative treatments for acute myeloid leukemia. These efforts reflect our commitment to offering patients access to the latest therapies while contributing to the future of cancer care.

To learn more, read the full article here: https://www.washingtonbusinessobserver.com/article/835794506-cero-therapeutics-doses-second-acute-myeloid-leukemia-patient-with-cer-1236 #

08/26/2025

💡Be Part of Light The Night! 💡

The Colorado Blood Cancer Institute team is proud to stand with our patients, caregivers, and community in the fight against blood cancer. We are once again partnering with The Leukemia & Lymphoma Society for Light The Night— an inspiring evening walk filled with hope, remembrance, and support for those impacted by blood cancers. And we want YOU to be there with us!

On ⭐Thursday, September 25⭐ at Wash Park, come raise your lantern for someone you love. Walk in honor, memory, or support of a patient or survivor. We encourage you to wear:
🧡 Gold for loved ones lost
❤️ Red for supporters
🤍 White for survivors and patients

➡️ Register today and walk with Team CBCI/HCA HealthONE Presbyterian St. Luke's: https://pages.lls.org/ltn/rm/DenverL25/CBCIPSLMCRMHC

Together, we can bring light to the darkness of cancer.

Light The Night At The Leukemia & Lymphoma Society’s Light The Night we gather as a community to celebrate, honor, and remember those touched by blood cancers. Friends, families, schools, corporate teams, and sponsors join together to bring light to the darkness of cancer. The funds raised by this...

08/21/2025

Even the busiest oncologists make time to give back—by donating blood.
Earlier this week, Dr. Gregory wrapped up a full clinic day and still rolled up a sleeve to help save lives.

If she can do it, you can too! Donate blood today. https://www.healthonecares.com/locations/blood-donor-center-at-presbyterian-st-lukes

08/09/2025

Huge congratulations to Drs. Scott Bearman, Jeffrey Matous, and Michael Tees of Colorado Blood Cancer Institute for being named 5280 Top Doctors! This prestigious honor reflects their exceptional care and dedication, recognized through a rigorous peer-nomination process. We’re honored to have these incredible physicians on our team!

08/07/2025

This month, we celebrated something truly extraordinary - Ruth’s 50th "workiversary" here at Colorado Blood Cancer Institute!

As an Apheresis Medical Technologist in our Cellular Therapeutics department, Ruth has dedicated five decades to helping patients, supporting her colleagues, and making a difference every single day. Her commitment, expertise, and heart inspire us all and remind us what makes CBCI such a special place to work.

Here’s to Ruth: 50 years of loyalty, excellence, and changing lives… and still going strong!

08/01/2025

Welcome Dr. Jonathan Lockhart!

We’re thrilled to welcome Jonathan Lockhart, MD, PhD to the Colorado Blood Cancer Institute team! Dr. Lockhart is a board-certified, fellowship-trained hematologist specializing in lymphoid malignancies, transplant, and cellular therapy, with a special focus on T cell malignancies, HIV-associated lymphomas, and innovative CAR T-cell therapies.

Originally from east Tennessee, Dr. Lockhart completed his MD/PhD at the University of Alabama at Birmingham, where his research focused on bone marrow transplantation and gene editing. He continued his training at Baylor College of Medicine, advancing cutting-edge CAR T research for T cell lymphomas.

At CBCI, Dr. Lockhart will be focusing on advancing care for
lymphoma and autoimmune disease. Please join us in giving him a warm welcome!

07/24/2025

We’re so proud to see our patient, Tom Grabiak of Erie, CO, featured as a BMT Infonet Spotlight Survivor!

Just before the new year in 2022, Tom was diagnosed with acute lymphoblastic leukemia (ALL). After intensive chemotherapy and a successful stem cell transplant here at Colorado Blood Cancer Institute in 2023, he’s back to living life fully—returning to work, rebuilding his strength, and even welcoming a beautiful baby boy with his husband this spring.

Tom’s story is a powerful reminder that with the right care team, determination, and hope, brighter days are ahead.

Read Tom’s inspiring journey on BMT Infonet:

I intentionally didn’t do a whole lot of reading about my prognosis or survival rates. I just trusted my health care team. I resolved to be a good patient and follow instructions and not introduce any information that might derail the process.

07/16/2025

The Colorado Blood Cancer Institute’s physician team includes some of the nation’s leading experts in blood cancer care. Dr. Jeffrey Matous was recently highlighted in "Targeted Oncology," where he shares how bispecific antibody therapy is transforming treatment for multiple myeloma. Learn more 👇
https://www.targetedonc.com/view/expanding-bispecific-antibody-use-in-community-oncology-practice

07/08/2025

The Colorado Blood Cancer Institute is proud to be FACT-accredited—an international gold standard in cellular therapy and stem cell transplant care. This accreditation from the Foundation for the Accreditation of Cellular Therapy (FACT) means we’ve voluntarily undergone rigorous on-site inspections, peer reviews, and a thorough evaluation of our procedures, providers, and patient care.

Why does this matter? It’s one more way we ensure that our patients receive the safest, highest-quality care possible.

Learn more about what FACT accreditation means for patients:
https://www.factglobal.org/accreditation-process/what-fact-accreditation-means-to-patients/

06/23/2025

In the News: Our clinical trials are important not only to our patients, but also to advancing the field of blood cancer treatment. Our team of talented providers and support staff work diligently to first care for patients while also compiling data and information that can be used to advance the treatment. One of our clinical trials involving CAR T-cell therapy was highlighted in a report, published online: https://www.openpr.com/news/3922510/marginal-zone-lymphoma-pipeline-2025-moa-and-roa-insights